Vilanterol
Last Updated: 04/28/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 405 publications
Fluticasone- vs Budesonide-Based Dual Therapy for COPD.
Journal: JAMA network open
Published: March 09, 2026
Molecular docking approaches in mycetoma: Toward improved patient management.
Journal: PLoS neglected tropical diseases
Published: February 11, 2026
A pragmatic, multicentre, placebo-controlled, 3-arm, double-blinded, randomised controlled trial, incorporating an internal pilot, to determine the role of bronchodilators in preventing exacerbations of bronchiectasis.
Journal: Health technology assessment (Winchester, England)
Published: February 09, 2026
Optimizing COPD management in Latin America: a cost-effectiveness analysis of FF/UMEC/VI in Colombia.
Journal: Expert review of pharmacoeconomics & outcomes research
Published: December 11, 2025
Is Clinical Remission, an Ambitious Treatment Goal, Achievable in Patients with Moderate-to-Severe Asthma on Inhaled Therapies: How Ambitious Should We Be?
Journal: Journal of clinical medicine
Published: December 10, 2025
Informing the US Medicare drug price negotiation for Trelegy Ellipta and Breo Ellipta: Evaluating the impact of real-world evidence.
Journal: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
Published: November 21, 2025
Mining of Adverse Event Signals Associated with Fluticasone Furoate/Umeclidinium/Vilanterol Triple Therapy: A Post-Marketing Analysis Based on FAERS.
Journal: Pharmacy (Basel, Switzerland)
Published: October 24, 2025
SERS fingerprinting of β2-agonists for anti-doping based on Au-COF substrate.
Journal: Analytica chimica acta
Published: October 09, 2025
Long-Acting Muscarinic Antagonists for the Treatment of Difficult-to-Treat and Severe Asthma: A Narrative Review Focusing on Inflammation from Bench to Bedside.
Journal: Journal of inflammation research
Published: October 02, 2025
Long-acting β2 agonist (LABA) with a long-acting muscarinic receptor antagonist (LAMA) promotes human airway smooth muscle (HASM) relaxation and circumvents β2 adrenergic receptor tachyphylaxis.
Journal: Respiratory research
Published: September 23, 2025
Sex-Specific Safety Signals of Trelegy Ellipta: A FAERS Pharmacovigilance Analysis.
Journal: Medical sciences (Basel, Switzerland)
Published: August 29, 2025
TETRIS - Prospective study to observe clinical outcomes of triple therapy in COPD patients: Up to 12 months interim analysis.
Journal: Respiratory medicine
Published: August 19, 2025
Last Updated: 04/28/2026